Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Dec;24(12):2249-62.
doi: 10.1007/s11095-007-9435-9. Epub 2007 Sep 11.

Computational models to assign biopharmaceutics drug disposition classification from molecular structure

Affiliations

Computational models to assign biopharmaceutics drug disposition classification from molecular structure

Akash Khandelwal et al. Pharm Res. 2007 Dec.

Abstract

Purpose: We applied in silico methods to automatically classify drugs according to the Biopharmaceutics Drug Disposition Classification System (BDDCS).

Materials and methods: Models were developed using machine learning methods including recursive partitioning (RP), random forest (RF) and support vector machine (SVM) algorithms with ChemDraw, clogP, polar surface area, VolSurf and MolConnZ descriptors. The dataset consisted of 165 training and 56 test set molecules.

Results: RF model 3, RP model 1, and SVM model 1 can correctly predict 73.1, 63.6 and 78.6% test compounds in classes 1, 2 and 3, respectively. Both RP and SVM models can be used for class 4 prediction. The inclusion of consensus analysis resulted in improved test set predictions for class 2 and 4 drugs.

Conclusions: The models can be used to predict BDDCS class for new compounds from molecular structure using readily available molecular descriptors and software, representing an area where in silico approaches could aid the pharmaceutical industry in speeding drugs to the patient and reducing costs. This could have significant applications in drug discovery to identify molecules that may have future developability issues.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Int J Clin Pharmacol Ther Toxicol. 1983 Aug;21(8):379-82 - PubMed
    1. J Med Chem. 2005 Feb 24;48(4):1287-91 - PubMed
    1. Ann Neurol. 1989 Aug;26(2):286-8 - PubMed
    1. Xenobiotica. 2003 Aug;33(8):841-54 - PubMed
    1. Br J Clin Pharmacol. 1998 Dec;46(6):553-61 - PubMed

Publication types

Substances